FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149439215> ?p ?o ?g. }

• W2149439215 endingPage "208" @default.
• W2149439215 startingPage "198" @default.
• W2149439215 abstract "The purpose of this article is to review, and make recommendations for, the use of relevant skin sensitization test methods, for the purposes of determination of relative potency and the threshold dose necessary for the induction of skin sensitization, and for risk assessment. In addressing the first area, the utility of three guinea pig tests (the guinea pig maximization test, the occluded patch test, and the open epicutaneous test) of the local lymph node assay (LLNA) and of human volunteer testing for the assessment of relative potency and identification of thresholds for sensitization were considered. The following conclusions were drawn. (1) Although attempts have been made to modify the guinea pig maximization test for the purposes of deriving dose-response relationships, this method is usually unsuitable for determination of relative sensitizing potency. (2) Guinea pig methods that do not require the use of adjuvant and which employ a relevant route of exposure (the occluded patch test and the open epicutaneous test) are more appropriate for the assessment of relative skin-sensitizing potency. (3) The LLNA is suitable for the determination of relative skin sensitizing potency, and the adaptation of this method for derivation of comparative criteria such as EC3 values (the estimated concentration of test chemical required to induce a stimulation index of 3 in the LLNA) provides an effective and quantitative basis for such measurements. (4) For all the methods identified above, potency is assessed relative to other chemical allergens of known skin sensitizing potential. The estimation of likely threshold concentrations is dependent upon the availability of suitable benchmark chemicals of known potency for human sensitization. (5) Human testing (and specifically, the Human Repeat Insult Patch Test) can provide information of value in confirming the absence of skin sensitizing activity of formulations and products under specific conditions of use and exposure. Based on the above, the following recommendations are made. (1) If results are already available from suitable guinea pig tests, then judicious interpretation of the data may provide information of value in assessing relative skin sensitizing potency. This option should be explored before other analyses are conducted. (2) The LLNA is the recommended method for new assessments of relative potency, and/or for the investigation of the influence of vehicle or formulation on skin sensitizing potency. (3) Whenever available, human skin sensitization data should be incorporated into an assessment of relative potency. With respect to risk assessment, the conclusion drawn is that all the available data on skin-sensitizing activity in animals and man should be integrated into the risk-assessment process. Appropriate interpretation of existing data from suitable guinea pig studies can provide valuable information with respect to potency, as the first step in the development of a risk assessment. However, for de novo investigations, the LLNA is the method favored for providing quantitative estimations of skin-sensitizing potency that are best suited to the risk assessment process. Finally, human testing is of value in the risk assessment process, but is performed only for the purposes of confirming product safety." @default.
• W2149439215 created "2016-06-24" @default.
• W2149439215 creator A5000606445 @default.
• W2149439215 creator A5009457494 @default.
• W2149439215 creator A5017250291 @default.
• W2149439215 creator A5019104680 @default.
• W2149439215 creator A5024073654 @default.
• W2149439215 creator A5036658219 @default.
• W2149439215 creator A5052081824 @default.
• W2149439215 creator A5063411693 @default.
• W2149439215 creator A5064982354 @default.
• W2149439215 creator A5065813134 @default.
• W2149439215 creator A5081341403 @default.
• W2149439215 creator A5085384594 @default.
• W2149439215 date "2001-02-01" @default.
• W2149439215 modified "2023-10-17" @default.
• W2149439215 title "Skin Sensitization Testing in Potency and Risk Assessment" @default.
• W2149439215 cites W1753071495 @default.
• W2149439215 cites W1925768879 @default.
• W2149439215 cites W19330218 @default.
• W2149439215 cites W1963577642 @default.
• W2149439215 cites W1967355125 @default.
• W2149439215 cites W1969506752 @default.
• W2149439215 cites W1972007630 @default.
• W2149439215 cites W1972130271 @default.
• W2149439215 cites W1972609440 @default.
• W2149439215 cites W1976934328 @default.
• W2149439215 cites W1992110036 @default.
• W2149439215 cites W1992391184 @default.
• W2149439215 cites W1992587784 @default.
• W2149439215 cites W1995449980 @default.
• W2149439215 cites W1997495107 @default.
• W2149439215 cites W1997975091 @default.
• W2149439215 cites W2002022057 @default.
• W2149439215 cites W2004590673 @default.
• W2149439215 cites W2007559030 @default.
• W2149439215 cites W2011673092 @default.
• W2149439215 cites W2013600449 @default.
• W2149439215 cites W2016655072 @default.
• W2149439215 cites W2018691571 @default.
• W2149439215 cites W2019786029 @default.
• W2149439215 cites W2021080814 @default.
• W2149439215 cites W2021905476 @default.
• W2149439215 cites W2023956205 @default.
• W2149439215 cites W2027473270 @default.
• W2149439215 cites W2027920382 @default.
• W2149439215 cites W2028598695 @default.
• W2149439215 cites W2032536307 @default.
• W2149439215 cites W2034475424 @default.
• W2149439215 cites W2037637757 @default.
• W2149439215 cites W2041555490 @default.
• W2149439215 cites W2041795762 @default.
• W2149439215 cites W2043484925 @default.
• W2149439215 cites W2045829430 @default.
• W2149439215 cites W2047973382 @default.
• W2149439215 cites W2052803693 @default.
• W2149439215 cites W2052890177 @default.
• W2149439215 cites W2053228091 @default.
• W2149439215 cites W2056080526 @default.
• W2149439215 cites W2056273798 @default.
• W2149439215 cites W2057282132 @default.
• W2149439215 cites W2061689899 @default.
• W2149439215 cites W2066522129 @default.
• W2149439215 cites W2070082546 @default.
• W2149439215 cites W2072778655 @default.
• W2149439215 cites W2081674927 @default.
• W2149439215 cites W2090048546 @default.
• W2149439215 cites W2090321465 @default.
• W2149439215 cites W2093432130 @default.
• W2149439215 cites W2093971130 @default.
• W2149439215 cites W2095331785 @default.
• W2149439215 cites W2105596726 @default.
• W2149439215 cites W2115120546 @default.
• W2149439215 cites W2116387860 @default.
• W2149439215 cites W2118609819 @default.
• W2149439215 cites W2129503157 @default.
• W2149439215 cites W2210301912 @default.
• W2149439215 cites W2271324327 @default.
• W2149439215 cites W2308236116 @default.
• W2149439215 cites W2310822049 @default.
• W2149439215 cites W2320672453 @default.
• W2149439215 cites W2412817939 @default.
• W2149439215 cites W615170570 @default.
• W2149439215 cites W656910037 @default.
• W2149439215 cites W2074758045 @default.
• W2149439215 doi "https://doi.org/10.1093/toxsci/59.2.198" @default.
• W2149439215 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11158712" @default.
• W2149439215 hasPublicationYear "2001" @default.
• W2149439215 type Work @default.
• W2149439215 sameAs 2149439215 @default.
• W2149439215 citedByCount "150" @default.
• W2149439215 countsByYear W21494392152012 @default.
• W2149439215 countsByYear W21494392152013 @default.
• W2149439215 countsByYear W21494392152014 @default.
• W2149439215 countsByYear W21494392152015 @default.
• W2149439215 countsByYear W21494392152016 @default.
• W2149439215 countsByYear W21494392152017 @default.
• W2149439215 countsByYear W21494392152018 @default.

• next